scholarly journals Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models

Open Biology ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. 180138 ◽  
Author(s):  
Era Taoufik ◽  
Georgia Kouroupi ◽  
Ourania Zygogianni ◽  
Rebecca Matsas

Synaptic dysfunction in CNS disorders is the outcome of perturbations in physiological synapse structure and function, and can be either the cause or the consequence in specific pathologies. Accumulating data in the field of neuropsychiatric disorders, including autism spectrum disorders, schizophrenia and bipolar disorder, point to a neurodevelopmental origin of these pathologies. Due to a relatively early onset of behavioural and cognitive symptoms, it is generally acknowledged that mental illness initiates at the synapse level. On the other hand, synaptic dysfunction has been considered as an endpoint incident in neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's, mainly due to the considerably later onset of clinical symptoms and progressive appearance of cognitive deficits. This dichotomy has recently been challenged, particularly since the discovery of cell reprogramming technologies and the generation of induced pluripotent stem cells from patient somatic cells. The creation of ‘disease-in-a-dish’ models for multiple CNS pathologies has revealed unexpected commonalities in the molecular and cellular mechanisms operating in both developmental and degenerative conditions, most of which meet at the synapse level. In this review we discuss synaptic dysfunction in prototype neurodevelopmental and neurodegenerative diseases, emphasizing overlapping features of synaptopathy that have been suggested by studies using induced pluripotent stem-cell-based systems. These valuable disease models have highlighted a potential neurodevelopmental component in classical neurodegenerative diseases that is worth pursuing and investigating further. Moving from demonstration of correlation to understanding mechanistic causality forms the basis for developing novel therapeutics.

2020 ◽  
Vol 190 ◽  
pp. 101805 ◽  
Author(s):  
Angélica María Sabogal-Guáqueta ◽  
Alejandro Marmolejo-Garza ◽  
Vítor Passos de Pádua ◽  
Bart Eggen ◽  
Erik Boddeke ◽  
...  

2019 ◽  
Vol 39 ◽  
pp. 101488 ◽  
Author(s):  
Gabriela Louise de Almeida Sampaio ◽  
Gabriele Louise Soares Martins ◽  
Bruno Diaz Paredes ◽  
Carolina Kymie Vasques Nonaka ◽  
Katia Nunes da Silva ◽  
...  

2017 ◽  
Vol 21 ◽  
pp. 19-22 ◽  
Author(s):  
Eszter Varga ◽  
Csilla Nemes ◽  
István Bock ◽  
Zsuzsanna Táncos ◽  
Sára Berzsenyi ◽  
...  

Author(s):  
Rebekka Kühn ◽  
Aayushi Mahajan ◽  
Peter Canoll ◽  
Gunnar Hargus

Neurodegenerative dementias are the most common group of neurodegenerative diseases affecting more than 40 million people worldwide. One of these diseases is frontotemporal dementia (FTD), an early onset dementia and one of the leading causes of dementia in people under the age of 60. FTD is a heterogeneous group of neurodegenerative disorders with pathological accumulation of particular proteins in neurons and glial cells including the microtubule-associated protein tau, which is deposited in its hyperphosphorylated form in about half of all patients with FTD. As for other patients with dementia, there is currently no cure for patients with FTD and thus several lines of research focus on the characterization of underlying pathogenic mechanisms with the goal to identify therapeutic targets. In this review, we provide an overview of reported disease phenotypes in induced pluripotent stem cell (iPSC)-derived neurons and glial cells from patients with tau-associated FTD with the aim to highlight recent progress in this fast-moving field of iPSC disease modeling. We put a particular focus on genetic forms of the disease that are linked to mutations in the gene encoding tau and summarize mutation-associated changes in FTD patient cells related to tau splicing and tau phosphorylation, microtubule function and cell metabolism as well as calcium homeostasis and cellular stress. In addition, we discuss challenges and limitations but also opportunities using differentiated patient-derived iPSCs for disease modeling and biomedical research on neurodegenerative diseases including FTD.


Sign in / Sign up

Export Citation Format

Share Document